SkyePharma seeks new capital for bond buyback

By Nina Flitman
03 Apr 2014

SkyePharma, the UK pharmaceutical company, is set to restructure its balance sheet with a big share issuance to be used to retire debt.

The capital increase, through a firm placing, and placing and open offer, will be priced at 191p per new share, with 11 new shares available for every 9 already held.

The up to 58.7m new shares sold represent around 127% of the company’s existing share capital. The total ...

Already a subscriber?

Continue reading this article

Try full access to GlobalCapital

Free trial